ERAS at a glance
Erasca, Inc. (ERAS, SEC CIK 1761918) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 24, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Erasca, Inc. (ERAS) shares worth $1.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Garner Ebun on April 1, 2026 of 80,000 shares at $16.40 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 30 funds
- $1.4B · +1 vs prior quarter
- Latest 8-K
- Aug 24, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Precision oncology company focused exclusively on discovering and developing therapies targeting RAS/MAPK pathway-driven cancers
- New emphasis: Clinical-stage programs ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) initiated INDs May 2025, first clinical data expected H1/H2 2026
- Strategic shift: Termination of Novartis naporafenib license in June 2026 to prioritize differentiated RAS-targeting franchise development
- Quantitative metric: Addressing ~2.7 million annual global patients with RAS-mutant tumors, including over 2.2 million with KRAS mutations targeted by ERAS-4001
- Noteworthy fact: ERAS-0015 shows 8-21x higher cyclophilin A affinity and 5x more potent RAS inhibition preclinically versus leading competitor molecular glue
Risk Factors
- Regulatory risk from compliance with EU Clinical Trials Regulation (CTR) effective January 31, 2025 impacting multi-center trial approvals
- Geopolitical risk from potential delays and cost increases due to evolving U.S. tariff and import/export regulations affecting operations
- Operational risk in dependency on third-party contract manufacturing organizations (CMOs) for clinical and potential commercial product supply
- Competitive risk from rapid technological advances in biopharma potentially rendering Erasca's RAS/MAPK pathway approach obsolete
- Financial risk with $892.2M accumulated deficit and need for substantial capital beyond $242.7M raised in 2026 offering to fund operations into second half 2028
Management Discussion & Analysis
- No revenue generated; net loss $124.5M in 2025 vs $161.7M in 2024, improving by $37.1M
- Operating expenses down to $140.9M in 2025 from $179.6M in 2024; R&D expense 22% lower at $92.9M vs $115.4M
- Best segment: ERAS-0015 R&D expense up to $26.9M from $6.7M; worst segment other clinical programs down from $58.3M to $32.8M
- Cash and equivalents $341.8M as of Dec 31, 2025; raised $242.7M net in Jan 2026 offering; $150M payment to Joyo in March 2026
- Expect Phase 1 data readouts 1H 2026 for ERAS-0015 and ERAS-4001; anticipate increased R&D and G&A expenses; cash sufficient through 2H 2028
AI summary of the ERAS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0; no products approved or revenue generated
- Net loss $44.1M vs $33.9M YoY for quarter ended June 30, 2026
- Best program ERAS-0015: 57% uORR at 32 mg QD in 2L+ KRAS G12X PDAC
- Cash, equivalents, and marketable securities $384.3M at June 30, 2026
- July offering added $593.5M net; expenses and operating losses expected to increase substantially
Risk Factors
- New IP infringement risk: RevMed’s April 24, 2026 letter alleges ERAS-0015 infringes U.S. Patent No. 12,409,225
- Most material legal update: RevMed demanded cessation of ERAS-0015 activities and comparative disclosures involving RMC-6236
- New securities litigation risk: June 10, 2026 class action alleges federal securities-law violations against Erasca and officers
- New governance litigation risk: August 2026 derivative complaint alleges fiduciary-duty and federal securities-law violations
- Operational impact: Potential injunctions, damages, licensing needs, or development-plan changes for ERAS-0015
AI summary of the ERAS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- FDA Fast Track Designation granted to ERAS-0015 for metastatic pancreatic adenocarcinoma
- Potential benefits: more frequent FDA interaction, rolling review, priority review, or accelerated approval eligibility
Item 2.02: Results of Operations and Financial Condition
- Erasca announced financial results for the three months ended June 30, 2026
- Full results and management commentary are provided in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- ERAS-0015 showed 57% 8-week uORR in 2L+ KRAS G12X PDAC at 32 mg QD, supporting accelerated pancreatic-cancer development
- Favorable safety profile: no DLTs or treatment-related discontinuations, with 100% median relative dose intensity
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Charles S. Fuchs appointed President, Research & Development effective August 10, 2026
- Oncology veteran brings Roche, Genentech, Yale Cancer Center, and Tubulis leadership experience
AI summaries of ERAS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ERAS
Don't miss the next ERAS filing
- Alerts as it files. A push when ERAS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ERAS, by share count.
- Ask anything. An AI agent that reads every ERAS filing and answers with sources.
ERAS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fuchs Charles S. | A | Aug 10, 2026 | 1,300,000 | - |
| Casdin Alexander W. | A | Jun 26, 2026 | 29,888 | - |
| Multani Pratik S | A | Jun 26, 2026 | 29,888 | - |
| Start Valerie Denise Harding | A | Jun 26, 2026 | 29,888 | - |
| Bristol James Arthur | A | Jun 26, 2026 | 29,888 | - |
| Hambleton Julie | A | Jun 26, 2026 | 29,888 | - |
| LIU JEAN I | A | Jun 26, 2026 | 29,888 | - |
| Garner Ebun | Sell | Apr 1, 2026 | 80,000 | $16.40 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$141.5M | -$179.6M | -$140.9M |
| Net Income | -$125.0M | -$161.7M | -$124.5M |
| Balance Sheet | |||
| Total Assets | $395.3M | $502.5M | $396.2M |
| Equity | - | $423.5M | $325.2M |
| ROE | - | -38.2% | -38.3% |
| Per Share | |||
| EPS | $-0.83 | $-0.69 | $-0.44 |
| Cash Flow | |||
| Operating CF | -$101.2M | -$109.4M | -$95.5M |
| CapEx | $1.8M | $60K | $128K |
Source: XBRL data in Erasca, Inc. (ERAS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ERAS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $1.38B |
| Q1 2026 | 29 | $1.07B |
| Q4 2025 | 23 | $191.8M |
| Q3 2025 | 24 | $106.2M |
| Q2 2025 | 26 | $60.7M |
| Q1 2025 | 23 | $45.1M |
| Q4 2024 | 18 | $88.7M |
| Q3 2024 | 17 | $53.6M |
- T. Rowe Price Group+4.46M (+246%)
- State Street Corp+2.88M (+31%)
- FMR LLC (Fidelity)+1.39M (+94%)
- BlackRock+1.00M (+5%)
- Citigroup+664.4K (+1353%)
- Goldman Sachs Group−1.05M (-22%)
- JPMorgan Chase & Co−423.8K (-46%)
- Citadel Advisors LLC−403.6K (-81%)
- Prudential Financial−383.7K (-92%)
- Morgan Stanley−373.2K (-38%)
- Mangrove Partners+15.7K
- Principal Financial Group+15.3K
- Raymond James Financial−82.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 190 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ERAS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 4 | Apr 3, 2026 | - | - | - |
| 10-K | Mar 12, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Mar 12, 2026 | - | Analysis | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Jan 30, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ERAS SEC filings: frequently asked questions
Which institutions hold ERAS stock?
As of June 30, 2026, the largest Erasca, Inc. (ERAS) holders among the 13F filers tracked by SignalX were BlackRock ($387.5 million), State Street Corp ($223.2 million), Vanguard Capital Management LLC ($208.9 million), T. Rowe Price Group ($114.9 million), Goldman Sachs Group ($70.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in ERAS's latest 10-K?
In the 10-K filed March 12, 2026, Erasca, Inc. (ERAS) flagged: Regulatory risk from compliance with EU Clinical Trials Regulation (CTR) effective January 31, 2025 impacting multi-center trial approvals. Geopolitical risk from potential delays and cost increases due to evolving U.S. tariff and import/export regulations affecting operations. (AI summary of the Risk Factors section.)
What did ERAS report in its latest 8-K?
Erasca, Inc. (ERAS) filed an 8-K on August 24, 2026 reporting Item 8.01 (Other Events). FDA Fast Track Designation granted to ERAS-0015 for metastatic pancreatic adenocarcinoma.
What are the latest ERAS SEC filings?
Erasca, Inc. (ERAS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 24, 2026 and a Form 4 insider filing on August 12, 2026.
What is ERAS's SEC CIK number?
Erasca, Inc. (ERAS)'s SEC Central Index Key (CIK) is 1761918. EDGAR lists every ERAS filing under that number.
Ask anything about ERAS
The research agent reads ERAS's filings, financials, insider trades and 13F holders, then answers with sources.